Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-22T04:21:30.323Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotic treatment in schizophrenia: atypical options and NICE guidance

Published online by Cambridge University Press:  16 April 2020

Ann M. Mortimer
Get access

Abstract

Following the reintroduction of clozapine, several atypical antipsychotics have become available for the treatment of schizophrenia. These drugs are at least as effective as conventional treatment. Although each has an individual pattern of affinities, new work suggests that the hallmark of atypicality is fast dissociation at the dopamine-2 receptor. Numerous novel drugs are in development, but it is not clear how these conform to this theory of therapeutic effect. Atypical antipsychotics cause less extrapyramidal side effects than conventional treatment, but other effects such as hyperprolactinaemia, weight gain, glucose dysregulation and prolonged QTc interval remain problematic for some. Current antipsychotic prescribing practice is far from ideal: the NICE guidance stresses that atypical treatments should be considered unless symptoms are well controlled and side effects are acceptable, or depot formulation is indicated. There is a welcome emphasis on drug treatment as part of an integrated package of care negotiated with patients and their carers.

Keywords

Atypical antipsychoticSchizophreniaNovel drug discoverySide effectsNICE guidance
Type
Original article
Information
European Psychiatry , Volume 18 , Issue 5 , August 2003 , pp. 209 - 219
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adams, C, The Cochrane Schizophrenia Group. Drug treatments for schizophrenia, 5. NHS Centre for Reviews and Dissemination; 1999 Effective Health Care [report].Google Scholar
Allison, DB, Mentmore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686–96.Google ScholarPubMed
Ames, D, Wirshing, WC, Marshall, BD.Risperidone versus haloperidol in treatment resistant schizophrenia. Schizophrenia Res 1997;24:193–4.CrossRefGoogle Scholar
Arvanitis, LA, Miller, BG, the Seroquel Trial Study Group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233–46.CrossRefGoogle Scholar
Bahr, BA, Bendiske, J, Brown, QB, Munirathinam, S, Caba, E, Rudin, M, et al. Survival signaling and selective neuroprotection through glutamatergic transmission. Exp Neurol 2002;174(1):37–47.CrossRefGoogle ScholarPubMed
Barnas, C, Stuppack, CH, Miller, C, Haring, C, Sperner-Unterweger, B, Fleischhacker, WW. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms, a double blind trial versus haloperidol. Int Clin Psychopharmacol 1992;7:23–7.CrossRefGoogle Scholar
Barnes, TRE, Edwards, J.Antipsychotic drugs and their side effects. London: Academic Press; 1993.Google Scholar
Barnett, D. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia, 43. London: National Institute for Clinical Excellence; 2002 Technology Appraisal Guidance [report].Google Scholar
Beasley, CM, Hamilton, SH, Crawford, AM.Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125–37.CrossRefGoogle ScholarPubMed
Beasley, CM, Tollefson, G, Tran, P.Olanzapine versus haloperidol and placebo: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111–24.CrossRefGoogle ScholarPubMed
Biswasl, PN, Wilton, LV, Pearcel, GL, Freemantle, S, Shakir, SA.The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001; 15(4):265–71.CrossRefGoogle Scholar
Blin, O. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? Encephale 2000;26(Spec No 1): 7–11.Google ScholarPubMed
Bondolfi, G, Baumann, P, Dufour, H.Treatment resistant schizophrenia: experience with new antipsychotics. Eur Neuropsychopharmacol 1996;6(Suppl 2):2–25.CrossRefGoogle ScholarPubMed
Borison, RL, Arvanitis, LA, Miller, BG.A comparison of five fixed doses of ‘Seroquel’ (ICI 204, 636) with haloperidol and placebo in patients with schizophrenia. Schizophrenia Res 1996;18(2, 3):132.CrossRefGoogle Scholar
Borison, RL, Arvanitis, LA, Miller, BG, et al. ICI 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16: 158–69.CrossRefGoogle Scholar
Boyer, P, Lecrubier, Y, Peuch, AJ.Treatment of negative symptoms in schizophrenia with amisulpiride. Br J Psychiatry 1995;166:68–72.CrossRefGoogle Scholar
Breier, A, Buchanan, JR, Kirkpatrick, B.Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20–6.Google ScholarPubMed
Buchanan, RW, Kreyenbuhl, J, Zito, JM, Lehman, A.Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 2002;159(6):1035–43.CrossRefGoogle Scholar
Buse, JB. Metabolic side effects of antipsychotics: focus on hypergly-caemia and diabetes. J Clin Psychiatry 2002;63(Suppl 4):37–41.Google ScholarPubMed
Caliguiri, M, Lohr, JB, Jeste, DV.Parkinsonism in neuroleptic naive schizophrenic patients. Am J Psychiatry 1993;150(9):1343–8.Google Scholar
Cavazzoni, P, Baker, RW, Kwong, K, Hornbuckle, K, Hutchins, D, Jovanovic, L, et al. A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States [pamphlet]. 2002.Google Scholar
Clark, O, O’Carroll, R. An examination of the relationship between executive function and rehabilitation status in schizophrenia. Neuropsycholog Rehabilitat 2003 (in press).Google Scholar
Conley, R, Love, R, Kelly, DL, Bartko, JJ.Rehospitalisation rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863–8.CrossRefGoogle ScholarPubMed
Conley, R, Tamminga, CA, Bartko, JJ, Richardson, C, Peszke, M, Lingle, J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155(7): 914–20.CrossRefGoogle ScholarPubMed
Cooper, SJ, Butler, A, Tweed, J, Welch, C, Raniwalla, J.Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000;150(3):237–43.CrossRefGoogle ScholarPubMed
Cooper, SJ, Tweed, J, Raniwalla, J, Butler, A, Welch, C.A placebo-controlled comparison of zoptepine versus chlopromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 2000; 101(3):218–25.CrossRefGoogle Scholar
Coukell, AJ, Spencer, CM, Benfield, P.Amisulpiride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996;6(3): 237–56.CrossRefGoogle Scholar
Csernansky, JG. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346(1):16–22.CrossRefGoogle ScholarPubMed
Cummins, C, Stevens, A, Kisely, C. In: Milne, R, Stein, K, editors. The use of olanzapine as a first and second choice treatment in schizophrenia, 84. 1998. p. 1–50 The South and West Development and Evaluation Service [report].Google Scholar
Currier, GW, Simpson, GM.Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62(3):153–7.CrossRefGoogle ScholarPubMed
Czekalla, J, Kollach-Walker, S, Beasley, CM. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001;62(Suppl 2):35–40.Google ScholarPubMed
Dannion, J, Rein, W, Fleurot, O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpiride. Am J Psychiatry 1999;156:610–6.Google Scholar
Davis, JM, Schaffer, CB, Killian, GA.Important issues in the drug treatment of schizophrenia. Schizophrenia Bull 1980;6:70–87.Google ScholarPubMed
Davis, R, Janicak, PG.Risperidone: a new, novel (and better?) antipsychotic. Psychiatric Ann 1996;26:78–87.CrossRefGoogle Scholar
de Paulis, T.M-100907 (Aventis). Curr Opinion Investigation Drugs 2001;2(1):123–32.Google Scholar
Decina, P, Mukherjee, S, Bocola, V.Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Community Psychiatry 1994;45:1220–3.Google ScholarPubMed
Dev, V, Raniwalla, J.Quetiapine: a review of its safety in the management of schizophrenia. Drug Safety 2000;23(4):295–307.Google ScholarPubMed
Dose, M, Tempel, HD.Abuse potential on anticholinergics. Pharmacopsychiatry 2000;33(Suppl 1):43–6.CrossRefGoogle ScholarPubMed
Dwyer, DS, Bradley, RJ, Kablinger, AS, Freeman, AM3. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001;13(2):103–13.CrossRefGoogle ScholarPubMed
Ekesbo, A, Andren, PE, Gunne, LM, Tedroff, J.(–)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson’s disease. Neuroreport 1997;8(11):2567–70.Google Scholar
Ekesbo, A, Torstenson, R, Hartvig, P, Carlsson, A, Sonesson, C, Waters, N, et al. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C] SCH23390 and [11C] raclopride binding in primate brains. Neuropharmacology 1999;38(3):331–8.CrossRefGoogle Scholar
Emsley, RA, Raniwalla, J, Bailey, PJ, Jones, AM.A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000;15:121–31.CrossRefGoogle Scholar
Falsetti, AE. Risperidone for control of agitation in dementia patients. Am J Health-System Pharmacy 2000;57(9):862–70.CrossRefGoogle ScholarPubMed
Farde, L, Wiesel, FA, Halldin, C.Central dopamine-2 occupancy in schizophrenic patients treated with antipsychotic drugs. Arch General Psychiatry 1988;45:71–6.CrossRefGoogle Scholar
Finn, C. Risperdal long acting microspheres. In: Mortimer, AM, editor. 2001 26–9-2001 [personal communication].Google Scholar
Freeman, HL. Amisulpiride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 1997;12(Suppl 2):11–7.CrossRefGoogle Scholar
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P.Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000;321:1371–6.Google ScholarPubMed
Glassman, AH, Bigger, JT.Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11):1774–82.CrossRefGoogle ScholarPubMed
Goff, DC, Leahy, I, Berman, I, Posever, T, Herz, L, Leon, AC, et al. A placebo-controlled study of the ampakiine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21(5):484–7.CrossRefGoogle Scholar
Goff, DC, Posever, T, Herz, L, Simmons, J, Kletti, N, Lapierre, K, et al. An exploratory haloperido-controlled dose-finding study of ziprasidone in hospitalised patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18(4):296–304.CrossRefGoogle ScholarPubMed
Green, B. Focus on risperidone. Curr Med Res Opinion 2000;16(2): 57–65.CrossRefGoogle ScholarPubMed
Gunasekara, NS, Spencer, CM, Keating, GM.Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2002; 62(8):1217–51.Google ScholarPubMed
Gunn, KPZiprasidone: safety and efficacy. Schizophrenia Res 1996; 18:132–3.Google Scholar
Haddad, P. QTc prolongation and schizophrenia: managing the risks. Progr Neurology Psychiatry 2001(Suppl):2–11.Google Scholar
Haupt, DW, Newcomer, J.Hyperglycaemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15–26.Google ScholarPubMed
Hellewel, JSE. Efficacy of quetiapine in aggression and hostility in schizophrenia. Presented at the Association of European Psychiatry Congress, 1998. 1998.Google Scholar
Hellewel, JSE, Kalali, A, Langham, S, McKellar, J.Patients’ satisfaction and acceptability of long-term treatment with ‘seroquel’: results of an international study. Presented at the ECNP, 1997. 1997.Google Scholar
Henderson, DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16(2):77–89.CrossRefGoogle ScholarPubMed
Henderson, DC, Cagliero, E, Gray, C, Nasrallah, HA, Hayden, DL, Schoenfeld, DA.Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157:975–81.CrossRefGoogle ScholarPubMed
Hwang, TJ, Lin, SK, Lin, H-N. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formosan Med Assoc 2001;100(12):811–6.Google ScholarPubMed
Jain, KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opinion Investigation Drugs 2000;9(12):2935–43.CrossRefGoogle ScholarPubMed
Joffe, G, Appelberg, B, Rimon, R.Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study. Int Clin Psychopharmacol 1999;14:233–8.Google Scholar
Johnson, SA, Luu, NT, Herbst, TA, Knapp, R, Lutz, D, Arai, A, et al. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther 1999;289(1):392–7.Google ScholarPubMed
Johnstone, EC, Crow, TJ, Ferrier, IN, Frith, CD, Owens, DGC, Bourne, RC, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psycholog Med 1983;13(3): 513–27.Google ScholarPubMed
Kane, J, Honigfeld, G, Singer, J.Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch General Psychiatry 1988;45:789–96.Google ScholarPubMed
Kapur, S, Remington, G.Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50(11):873–83.CrossRefGoogle ScholarPubMed
Kapur, S, Seeman, P.Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158(3):360–9.Google ScholarPubMed
Karagianis, JL, Dawe, IC, Thakur, A, Raskin, J, Roychowdhury, SM.Rapid tranquillization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001;62(Suppl 2):12–6.Google Scholar
Kasper, S, Quiner, S, Barnas, C, Fabisch, H, Haushofer, M, Sackel, C, et al. Zotepine in the treatment of acute hospitalized schizophrenic episodes. Int Clin Psychopharmacol 2001;16(3):163–8.CrossRefGoogle ScholarPubMed
Keck, P, Buffenstein, A, Ferguson, J, Feighner, J, Jaffe, W, Harrigan, EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998;140(2):173–84.CrossRefGoogle ScholarPubMed
King, DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Psychopharmacology 1998;8:33–42.Google ScholarPubMed
Kirov, GK, Murray, RM, Seth, RV, Feeney, S.Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychi-atr Scand 1997;95:439–43.CrossRefGoogle ScholarPubMed
Kopala, LC, Fredrikson, D, Good, KP, Honer, WG.Symptoms in neuroleptic-naive, first episode schizophrenia: response to risperidone. Biol Psychiatry 1996;39:296–8.CrossRefGoogle Scholar
Kopala, LC, Good, KP, Fredrikson, D, Whitehorn, D, Lazier, L, Honer, WG.Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs. International J Psychiatry Clin Practice 1998;2(Suppl 1):19–25.Google Scholar
Kopala, LC, Good, KP, Honer, WG.Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17(4):308–13.Google ScholarPubMed
Kopelowicz, A, Zarate, R, Tripodis, K, Gonzalez, V, Mintz, J.Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157(6):987–93.CrossRefGoogle Scholar
Lane, HY, Chiu, WC, Chou, JC, Wu, ST, Su, MH, Chang, WH.Risperi-done in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000;61(3):209–14.CrossRefGoogle Scholar
Launer, M. Zotepine and nefazadone for clozapine ‘reds’. In: Mortimer, AM, editor. 2002 [personal communication].Google Scholar
Lawler, CP, Prioleau, C, Lewis, MM, Mak, C, Jiang, D, Schetz, JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612–27.CrossRefGoogle ScholarPubMed
Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W.Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Res 1999;35(1):51–68.CrossRefGoogle ScholarPubMed
Leysen, JE, Gommeren, W, Schotte, A.Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane, JM, Moller, H-J, Awouters, F, editors. Serotonin in antipsychotic treatment. New York: Marcel Dekker, Inc; 1996. p. 51–75.Google Scholar
Lieberman, JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996; 57(Suppl 11):68–71.Google ScholarPubMed
Loo, H, Poirer-Littre, MF, Theron, M.Amisulpiride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18–22.CrossRefGoogle Scholar
Lund, BC, Perry, PJ, Brooks, JM, Arndt, S.Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidaemia, and hypertension: a claims-based approach. Arch General Psychiatry 2001;58(12):1172–6.CrossRefGoogle ScholarPubMed
Marder, SR. Antipsychotic drugs and relapse prevention. Schizophrenia Res 1999;35(Suppl 1):87–92.CrossRefGoogle ScholarPubMed
Marder, SR, Meibach, RC.Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825–35.Google ScholarPubMed
Martin, C. Impact of olanzapine on quality of life in schizophrenia. Eur Psychiatry 1996;11(Suppl 4):252 [abstract].CrossRefGoogle Scholar
Matsubayashi, H, Amano, T, Sasa, M.Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacologia 1999;146(2):139–43.CrossRefGoogle ScholarPubMed
McAllister-Williams RH, Ferrier, IN. Rapid tranquilisation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002; 179(485):489.Google Scholar
McManus, DQ, Arvanitis, LA, Kowalcyk, BB.Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999;60(5):292–8.CrossRefGoogle ScholarPubMed
Meyer-Lindenberg, A, Gruppe, H, Bauer, U, Lis, S, Krieger, S.Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30:35–42.CrossRefGoogle ScholarPubMed
Meyer, JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63(5):425–33.CrossRefGoogle ScholarPubMed
Millan, MJ, Schreiber, R, Monneyron, S, Denorme, B, Melon, C, Queriaux, S, et al. S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine. J Pharmacol Exp Ther 1999;289(1):427–36.Google ScholarPubMed
Mir, S, Taylor, D.Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16(2):63–73.CrossRefGoogle ScholarPubMed
Moller, H-J. Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatr Scand 2000;400(Suppl):17–22.CrossRefGoogle Scholar
Moller, H-J, Boyer, P, Fleurot, O, Rein, W.Improvement of acute exacerbations of schizophrenia with amisulpiride: a comparison with haloperidol. Psychopharmacology 1997;132:396–401.Google Scholar
Mortimer, AM. A clozapine cohort: outcome and issues of concern. Human Psychopharmacol 1997;12:361–3.3.0.CO;2-Q>CrossRefGoogle Scholar
Newcomer, J, Haupt, DW, Fucetola, R, Melson, AK, Schweiger, JA, Cooper, BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch General Psychiatry 2002; 59(4):337–45.CrossRefGoogle ScholarPubMed
Parsa, A, Bastani, B.Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1998;10(2):216–9.CrossRefGoogle ScholarPubMed
Petit, M, Raniwalla, J, Tweed, JA, Leutenegger, E, Dollfus, S, Kelly, F.A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996;32(1): 81–7.Google ScholarPubMed
Peuskens, J, Link, CGG. A comparison of quetiapine and chlopromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96:265–73.CrossRefGoogle Scholar
Pfizer LTD. Introducing new products to the schizophrenia market. In: Mortimer, AM, editor. Data on file, ZEL200/0702. 2002 [personal communication].Google Scholar
Pichot, P, Boyer, P.Adouble blind, controlled, multi-centre trial of low dose amisulpiride (Solian 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia. Ann Psychiatry 1988;3(3):312–20.Google Scholar
Poyurovsky, M, Pashinian, A, Gil-Ad, I, Maayan, R, Schneidman, M, Fuchs, C, et al. Olanzpine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002;159(6):1058–60.CrossRefGoogle ScholarPubMed
Procyshyn, RM, Zerjav, S.Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998;20(6):1203–17.CrossRefGoogle ScholarPubMed
Raniwalla, J, Tweed, JA, Dollfus, S, Petit, M.A comparison of an atypical (zotepine) and classical (haloperidol) antipsychotic in patients with acute exacerbation of schizophrenia. Schizophrenia Res 1996;18(2, 3):133.CrossRefGoogle Scholar
Ray, WA, Meador, KG.Antipsychotics and sudden death: is thioridazine the only bad actor? Br J Psychiatry 2002;180:483–4.CrossRefGoogle ScholarPubMed
Reeves, K, Harrigan, EP.The efficacy and safety of two fixed doses of ziprasidone in schizophrenia and schizoaffective disorder. Presented at the 149th annual meeting of the American Psychiatric Association, New York. 1996.Google Scholar
Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors: focus on new generation compounds. Life Sci 2000;68(1): 29–39.CrossRefGoogle Scholar
Russell, JM, Mackell, JA.Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001;15(7):537–51.CrossRefGoogle ScholarPubMed
Rymer, M, Williets, S, Shepherd, CJ, Mortimer, AM.An audit of antipsychotic prescribing in primary care 2002 [unpublished work].Google Scholar
Saletu, B, Kufferle, B, Grunberger, J.Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpiride and fluphenazine. Neuropsychobiology 1994;29(3):125–35.CrossRefGoogle Scholar
Sanger, T, Lieberman, JA, Tohen, M, Grundy, S, Beasley, CM, Tollefson, G. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156(1):79–87.CrossRefGoogle ScholarPubMed
Sciolla, A, Jeste, DV. Use of antipsychotics in the elderly. Int J Psychiatry Clin Practice 1998;2(Suppl 1):27–34.Google Scholar
Seeman, P. Dopamine/neuroleptic receptors in schizophrenia. In: Burrows, GD, Norman, TR, Rubinstein, G, editors. Handbook on studies of schizophrenia. Amsterdam: Elsevier; 1986.Google Scholar
Seeman, P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27–38.CrossRefGoogle ScholarPubMed
Sernyak, MJ, Leslie, DL, Alarcon, RD, Losonczy, M, Rosenheck, R.Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159(4):561–6.CrossRefGoogle ScholarPubMed
Silver, HSN. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998;18:208–11.CrossRefGoogle Scholar
Song, F. Risperidone in the treatment of schizophrenia: a neta-analysis of randomised controlled trials. J Psychopharmacol 1997;11:65–71.CrossRefGoogle Scholar
Speller, J, Barnes, TRE, Curson, DA. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms: amisulpiride v. haloperidol. Br J Psychiatry 1997;171:564–8.CrossRefGoogle Scholar
Stahl, SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60(Suppl 10):31–41.Google ScholarPubMed
Stahl, SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001;62(12):923–4.CrossRefGoogle ScholarPubMed
Stahl, SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptors. J Clin Psychiatry 2002;62(11):841–2.CrossRefGoogle Scholar
Sugiyama, A, Satoh, Y, Hashimoto, K.In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 2001;173(2):120–8.CrossRefGoogle Scholar
Swift, RH, Harrigan, EP, van Kammen, DP. A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol. Eur Neuropsychopharmacol 1998;8(Suppl 2):216.CrossRefGoogle Scholar
Tamminga, CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transmission-General Section 2002;109(3):411–20.CrossRefGoogle ScholarPubMed
Taylor, D. UK prescribing of antipsychotics and clozapine. In: Kerwin, RW, editor. The earlier use of clozaril: a discussion. London: The Workhouse; 2002. p. 15–20.Google Scholar
Taylor, D, McConnell, D, McConnell, H, Kerwin, RW.The Maudsley 2001 prescribing guidelines. 6th ed. London: Martin Dunitz; 2001.Google Scholar
Taylor, D, Mir, S, Mace, S, Whiskey, E.Co-prescribing of atypical and typical antipsychotics-prescribing sequence and documented outcome. Psychiatric Bull 2002;26:170–2.CrossRefGoogle Scholar
Taylor, DM, McAskill, R.Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 2000;101:416–32.CrossRefGoogle ScholarPubMed
Tedroff, J, Ekesbo, A, Sonesson, C, Waters, N, Carlsson, A. Long-lasting improvement following (-)-OSU6162 in a patient with Huntingdon’s disease. Neurology 1999;53(7):1605–6.CrossRefGoogle Scholar
Tedroff, J, Torstenson, R, Hartvig, P, Sonesson, C, Waters, N, Carlsson, A, et al. Effects of the substituted (S)-3-phenylpiperidiine (-)OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse 1998;28(4):280–7.3.0.CO;2-5>CrossRefGoogle Scholar
The Department of Health. The National Service Framework for Mental Health [bill/resolution]. 1999.Google Scholar
The Department of Health HMG. Modernising Mental Health Services: White Paper [bill/resolution]. 1997.Google Scholar
The Zito Trust. The practice gap in schizophrenia: are people with schizophrenia being given the best chance in life? Eli Lilly UK [pamphlet]. 2001.Google Scholar
Thompson, C. The use of high dose antipsychotic medication. Br J Psychiatry 1994;164:448–58.CrossRefGoogle ScholarPubMed
Tollefson, G, Sanger, T.Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:457–65.Google ScholarPubMed
Tollefson, G, Sanger, T, Lu, Y, Thieme, M.Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch General Psychiatry 1998;55:250–8.CrossRefGoogle ScholarPubMed
Tracy, JJ, Monaco, C, Giovannetti, T, Abraham, G, Josiassen, RC.Anticholinergicity and cognitive processing in chronic schizophrenia. Biol Psychiatry 2001;56(1):1–22.CrossRefGoogle ScholarPubMed
Tran, PV, Hamilton, SH, Kuntz, AJ, Potvin, JH, Andersen, SW, Beasley, C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407–18.Google ScholarPubMed
Tran, P, Shamir, E, Poyorovski, M, Lokshin, P, Weizer, N, Dorfman, P, et al. Olanzapine in the treatment of patients who failed to respond to or tolerate clozapine. Psychopharmacol Bull 1997;33(3): 599.Google Scholar
Tuunainen, A, Wahlbeck, K, Gilbody, SM.Newer antipsychotic medication versus clozapine for schizophrenia. Cochrane Database System Review 2000;2 [CD000966] [generic].Google Scholar
Tyson, PJ, Mortimer, AM, Wheeler, JA.High dose antipsychotic treatment in clinical practice: a review, audit and survey of consultant psychiatrist opinions. Psychiatric Bull 1999;23:661–4.CrossRefGoogle Scholar
Umbricht, D, Ames, D, Wirshing, WC.Predictors of response to clozapine in a long-term double blind treatment study. Schizophrenia Res 1997;24:189.Google Scholar
Warner, JP, Slade, R, Barnes, TRE. Change in neuroleptic prescribing practices. Psychiatric Bull 1995;19:237–9.CrossRefGoogle Scholar
Wassef, AA, Dott, SG, Harris, A, Brown, A, O’Boyle, M, Meyer, WJ, etal. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20(3):357–61.CrossRefGoogle ScholarPubMed
Weiden, P, Aquila, A, Standard, J.Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl 11):53–60.Google Scholar
Wetterling, T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety 2001;24(1):59–73.Google ScholarPubMed
World Health Organisation. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990; 156:412.CrossRefGoogle Scholar
Wright, P, Birkett, M, Meehan, K.A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Schizophrenia Res 2001; 49(Suppl 1):250–1.Google Scholar
Wright, P, Birkett, M, David, SR, Meehan, K.Double-blind, placebo-controlled comparison of intramuscular olanmzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149–51.CrossRefGoogle Scholar
Zarate, CA. Sudden cardiac death and antipsychotics. Arch General Psychiatry 2001;58(1168):1171.CrossRefGoogle Scholar
Zhang, XY, Zhou, DF, Cao, LY, Zhang, PY, Wu, GY, Shen, YC.Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol 2001;16(6):325–30.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.